Airlat Launches Joint Research with Leading Private Clinic in Asia for AI Radiation Therapy Treatment Planning Support
Airlat Inc. has commenced joint research and development with Asian Alliance Radiation & Oncology (AARO) in Singapore, focusing on AI elemental technology for prostate cancer radiation therapy treatment planning support. This collaboration aims to integrate AARO's clinical expertise with Airlat's AI technology to build an AI model adapted to Singapore's medical field, contributing to the improvement of radiation therapy quality in the Asian region.
📋 Article Processing Timeline
- 📰 Published: April 30, 2026 at 23:14
- 🔍 Collected: April 30, 2026 at 14:31
- 🤖 AI Analyzed: April 30, 2026 at 16:31 (1h 59m after Collected)
Airlat Inc., an AI development company in the field of radiation therapy (Head office: Sendai City, Miyagi Prefecture; Representative Directors: Yuji Kimura, Tomoyuki Kakuya), has signed a joint research agreement with Centre for Stereotactic Radiosurgery (CSR), the core facility of Asian Alliance Radiation & Oncology (hereinafter "AARO"), a specialized radiation therapy clinic group in Singapore, on April 20, 2026, to commence research and development of AI elemental technology for prostate cancer radiation therapy treatment planning support.
■ Background and Significance of this Joint Research
AARO was established in 2015 as Singapore's first independent private radiation therapy clinic group. Its founding members are radiation clinical oncologists from the National Cancer Centre Singapore (NCCS), with a track record of pioneering Stereotactic Body Radiation Therapy (SBRT) programs in Southeast Asia. In addition to CSR, its main treatment facility, AARO operates multiple consultation sites within major private hospitals in Singapore.
■ Outline of Joint Research
This research will utilize anonymized prostate cancer SBRT data provided by CSR to build and verify the usefulness of an AI model adapted to the clinical practice in Singapore. The study focuses on building and verifying AI models for specific organ sites, adapted to specialized clinical settings like CSR (Singapore), starting with prostate SBRT.
By using actual anonymized clinical data and welcoming AARO's specialists as research partners, an AI model that meets Singapore's real-world clinical needs will be constructed, contributing to the improvement of radiation therapy quality in the Asian region.
The research period is scheduled for one year from 2026, with an expansion to the next phase to be considered based on the results.
■ Comment from Yuji Kimura, Representative Director & CEO, Airlat Inc.
"We are greatly encouraged by the opportunity to collaborate with AARO, which has pioneered SBRT in Southeast Asia. We will integrate the knowledge cultivated on the clinical front lines with Airlat's AI technology to build an AI model tailored to Singapore's medical environment, starting with prostate cancer SBRT."
■ Comment from Dr. Daniel Tan, Founder of AARO and Board Member of the International Stereotactic Radiosurgery Society (ISRS)
"Our collaboration with Airlat's AI technology marks a significant milestone in AARO's journey. For our clinic, which launched the first prostate SBRT program in Singapore and the surrounding region over 10 years ago, gaining the opportunity to 'perpetuate' that knowledge as an AI model holds immense significance. Through this initiative, we aim to expand access to prostate SBRT treatment for more patients, including those at our partner facilities, while ensuring the highest standards of treatment planning quality for the future."
【About Airlat Inc.】
Airlat Inc. is a medical innovation company founded by healthcare professionals and researchers with firsthand knowledge of cancer treatment, united to change the future of cancer treatment through AI technology. Starting from challenges in the radiation therapy field, one of the cancer treatments, the company develops and provides medical AI products that continue to be used in clinical settings.
In the highly specialized field of radiation therapy planning, the company aims to support the quality of medical care and the sustainability of clinical sites.
Company Name: Airlat Inc.
Locations:
Headquarters: 468-1 Aoba, Aramaki, Aoba-ku, Sendai City, Miyagi Prefecture
Sendai Office: T-Biz, 6-6-40 Aoba, Aramaki, Aoba-ku, Sendai City, Miyagi Prefecture
Tokyo Office: 16F Sumitomo Fudosan Shibakoen Tower, 2-11-1 Shibakoen, Minato-ku, Tokyo
Representative Directors: Yuji Kimura, Tomoyuki Kakuya
Established: March 2022
Business Description: Development and provision of radiation therapy treatment planning support software utilizing AI.
Airlat Inc. Official Website (URL is missing)
■ Background and Significance of this Joint Research
AARO was established in 2015 as Singapore's first independent private radiation therapy clinic group. Its founding members are radiation clinical oncologists from the National Cancer Centre Singapore (NCCS), with a track record of pioneering Stereotactic Body Radiation Therapy (SBRT) programs in Southeast Asia. In addition to CSR, its main treatment facility, AARO operates multiple consultation sites within major private hospitals in Singapore.
■ Outline of Joint Research
This research will utilize anonymized prostate cancer SBRT data provided by CSR to build and verify the usefulness of an AI model adapted to the clinical practice in Singapore. The study focuses on building and verifying AI models for specific organ sites, adapted to specialized clinical settings like CSR (Singapore), starting with prostate SBRT.
By using actual anonymized clinical data and welcoming AARO's specialists as research partners, an AI model that meets Singapore's real-world clinical needs will be constructed, contributing to the improvement of radiation therapy quality in the Asian region.
The research period is scheduled for one year from 2026, with an expansion to the next phase to be considered based on the results.
■ Comment from Yuji Kimura, Representative Director & CEO, Airlat Inc.
"We are greatly encouraged by the opportunity to collaborate with AARO, which has pioneered SBRT in Southeast Asia. We will integrate the knowledge cultivated on the clinical front lines with Airlat's AI technology to build an AI model tailored to Singapore's medical environment, starting with prostate cancer SBRT."
■ Comment from Dr. Daniel Tan, Founder of AARO and Board Member of the International Stereotactic Radiosurgery Society (ISRS)
"Our collaboration with Airlat's AI technology marks a significant milestone in AARO's journey. For our clinic, which launched the first prostate SBRT program in Singapore and the surrounding region over 10 years ago, gaining the opportunity to 'perpetuate' that knowledge as an AI model holds immense significance. Through this initiative, we aim to expand access to prostate SBRT treatment for more patients, including those at our partner facilities, while ensuring the highest standards of treatment planning quality for the future."
【About Airlat Inc.】
Airlat Inc. is a medical innovation company founded by healthcare professionals and researchers with firsthand knowledge of cancer treatment, united to change the future of cancer treatment through AI technology. Starting from challenges in the radiation therapy field, one of the cancer treatments, the company develops and provides medical AI products that continue to be used in clinical settings.
In the highly specialized field of radiation therapy planning, the company aims to support the quality of medical care and the sustainability of clinical sites.
Company Name: Airlat Inc.
Locations:
Headquarters: 468-1 Aoba, Aramaki, Aoba-ku, Sendai City, Miyagi Prefecture
Sendai Office: T-Biz, 6-6-40 Aoba, Aramaki, Aoba-ku, Sendai City, Miyagi Prefecture
Tokyo Office: 16F Sumitomo Fudosan Shibakoen Tower, 2-11-1 Shibakoen, Minato-ku, Tokyo
Representative Directors: Yuji Kimura, Tomoyuki Kakuya
Established: March 2022
Business Description: Development and provision of radiation therapy treatment planning support software utilizing AI.
Airlat Inc. Official Website (URL is missing)